Clinical Trial Detail

NCT ID NCT02620423
Title Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Oncolytics Biotech
Indications

pancreatic adenocarcinoma

Therapies

Gemcitabine

Fluorouracil

Irinotecan

Reolysin

Leucovorin

Pembrolizumab

Age Groups: adult

No variant requirements are available.